Eli Lilly signs deal for MeiraGTx's gene therapy for severe eye disease
1. Eli Lilly signs a $475 million deal for gene therapy rights. 2. The therapy targets a rare inherited disorder causing severe vision loss.
FAQ
Why Bullish?
This deal enhances LLY's portfolio with innovative therapies, similar to past successful acquisitions like Allergan. Historical deals in biotech have typically led to positive long-term value creation.
How important is it?
Acquiring rights to a potentially impactful therapy could significantly strengthen LLY’s pipeline, suggesting substantial future revenue opportunities.
Why Long Term?
The agreement could gradually increase LLY's revenue streams as the therapy advances through clinical phases, similar to how recent acquisitions have taken time to mature and generate returns.